Safety and Efficacy of Aliskiren in Post Myocardial Infarction Patients (ASPIRE)

Completed · Phase 3 · Has a placebo group

Conditions studied: Myocardial Infarction

In brief

The core and extension studies assessed the safety and efficacy of aliskiren when added to optimized standard therapy in patients that have had a high risk acute myocardial infarction (heart attack).

Key facts

Study ID

NCT00414609

Run by

Novartis

People needed

820

Starts

2006-12-01

Expected to finish

2011-07-01

Last updated by the study team

2012-07-13

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Novartis US — Novartis US, New Jersey, United States
• Novartis Argentina — Novartis Argentina, Argentina
• Novartis Belgium — Novartis Belgium, Belgium
• Novartis Canada — Novartis Canada, Canada
• Novartis de Colombia S.A. — Bogotá, Colombia
• Novartis Czech Republic — Prague, Praha 3, Czechia
• Novartis Denmark — Novartis Denmark, Denmark
• Novartis Germany — Novartis Germany, Germany
• Novartis Hungary — Budapest, Budapest, Hungary
• Novartis Healthcare Private Limited — Worli, Mumbai, India
• Novartis Pharma — Petah Tikva, Petach Tikva, Israel
• Novartis Italy — Novartis Italy, Italy
• Novartis Netherlands — Novartis Netherlands, Netherlands
• Novartis Norway — Novartis Norway, Norway
• Novartis Poland Sp. z o.o. — Warsaw, Poland
• Novartis Russia — Novartis Russia, Russia
• Novartis Slovakia — Bratislava, Bratislava Region, Slovakia
• Novartis Korea Ltd. — Seoul, Seoul, South Korea
• Novartis Spain — Novartis Spain, Spain
• Novartis Sweden — Novartis Sweden, Sweden
• Novartis Turkey — Istanbul, Istanbul, Turkey (Türkiye)
• Novartis UK — Novartis, United Kingdom
• Novartis de Venezuela, S.A. — Caracas, Venezuela

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.